Heart Failure clinical trials at UC Irvine
7 in progress, 3 open to eligible people
Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation
open to eligible people ages 18 years and up
The study is being done to see if ziltivekimab can be used to treat participants living with heart failure and inflammation. Participants will either get ziltivekimab (active medicine) or placebo (inactive substance that looks like the study medicine but does not contain any medicine). The treatment participants get is decided by chance. Participant's chance of getting ziltivekimab or placebo is the same. Ziltivekimab is not yet approved in any country or region in the world. It is a new medicine that doctors cannot prescribe. The study is expected to last for up to 1 year and 4 months.
Orange, California and other locations
Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation
open to eligible people ages 18 years and up
This study will be done to see if ziltivekimab can be used to treat people living with heart failure and inflammation. Participants will either get ziltivekimab or placebo. Participants will get study medicine for once-monthly injections either in a pre-filled syringe to inject the study medicine into a skinfold or a pen-injector to inject the study medicine into flat skin. The study is expected to last for up to 4 years. Participants will have up to 20 clinic visits. Participants will have to use a study app on their phone to record and share information about all their injections of study medicine and to fill in questionnaires.
Orange, California and other locations
ALT-FLOW II Trial of the Edwards APTURE Transcatheter Shunt System
open to eligible people ages 18 years and up
This is a prospective, multi-center, randomized, sham-controlled, double-blinded (participant and outcomes assessor) clinical trial.
Irvine, California and other locations
Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)
Sorry, in progress, not accepting new patients
This is a Phase 2, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of sotatercept versus placebo in adults with Cpc-PH due to HFpEF. The objective of this study is to evaluate the efficacy, safety and tolerability of sotatercept versus placebo in adults with Cpc-PH due to HFpEF. Efficacy is measured by change from baseline in pulmonary vascular resistance (PVR, primary endpoint) and 6-minute walk distance (6MWD, key secondary endpoint).
Orange, California and other locations
Fluid Management of Acute Decompensated Heart Failure Subjects Treated with Reprieve System (FASTR-II)
Sorry, not yet accepting patients
The objective of this study is to prospectively compare decongestive therapy administered by the Reprieve System to Optimal Diuretic Therapy (ODT) in the treatment of patients diagnosed with acute decompensated heart failure (ADHF). The main objective is to determine if the Reprieve System can more efficiently decongest ADHF patients in comparison to Control Therapy.
Irvine, California and other locations
LUX-Dx TRENDS Evaluates Diagnostics Sensors in Heart Failure Patients Receiving Boston Scientific's Investigational ICM System.
Sorry, in progress, not accepting new patients
The primary objective of this study is to collect sensor data from insertable cardiac monitor systems.
Orange, California and other locations
AT-001 in Patients With Diabetic Cardiomyopathy
Sorry, in progress, not accepting new patients
This is a multicenter, randomized, placebo-controlled, 2-part study to evaluate the safety and efficacy of AT-001 in adult patients (N=675) with Diabetic Cardiomyopathy at high risk of progression to overt heart failure.
Orange, California and other locations
Last updated: